Adenosine Triphosphate-Citrate Lyase Inhibitor Drug Class List

Drugs in Drug Class: Adenosine Triphosphate-Citrate Lyase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes				Y

Last updated: June 30, 2026

Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitor Market Dynamics and Patent Landscape: Key Patents, Exclusivity Timelines, and Generic/Biosimilar Risk

Executive summary

• The “adenosine triphosphate-citrate lyase (ACL) inhibitor” class is led by ATP-citrate lyase (ACLY) inhibitors, with the commercial and clinical pipeline concentrated in oncology and metabolic disease indications.
• The patent estate is typically split across: core chemical entities (small-molecule composition-of-matter), process/manufacturing, formulations, and method-of-use (biomarkers and specific therapeutic regimens).
• Exclusivity bottlenecks are driven less by broad class monopolies and more by drug-specific compositions and method-of-use patents plus regulatory exclusivity (notably NCE or new formulation exclusivity where applicable).
• Generic entry risk is dominated by whether Orange Book-listed patents exist for the relevant NDA ANDAs and whether challengers can design around formulation and method-of-use claims.
• Biosimilar risk is limited because ACL inhibitors are small molecules (biosimilar pathways do not apply in the standard regulatory framework for this drug class).

---

Which ATP-citrate lyase (ACLY) inhibitors have meaningful market presence?

Featured snippet answer: Market presence in the ACL inhibitor space is drug-specific, led by a small number of ACLY inhibitors rather than multiple parallel commercial products.

Drug class scope: ACL/ACLY inhibition

• Target: ATP-citrate lyase (ACLY), which links mitochondrial citrate export to cytosolic lipid synthesis through acetyl-CoA generation.
• Typical therapeutic hypotheses: tumor lipid metabolism dependence, metabolic diseases linked to lipid synthesis, and combination regimens in cancer.

Companies active in ACLY inhibitor development

Market dynamics in this niche are shaped by:

• small-molecule discovery platforms,
• partnership structures for late-stage oncology programs,
• rapid patent “thickets” built around lead series optimization.

Patent strategy pattern across the class

• Early filing: compound series + scaffolds
• Follow-on filings: salt forms, polymorphs, intermediates, formulation coatings, and dosing regimens
• Regulatory timing: reliance on later filings for extension of claim coverage around clinical endpoints

---

What patents protect ACL inhibitors (ACLY inhibitors): composition-of-matter, methods, and formulations?

Featured snippet answer: ACL inhibitor patent protection usually stacks compound claims with method-of-use and formulation patents, producing multiple independent routes to infringement and multiple fallback positions for settlement.

Patent categories that matter for enforcement

1. Composition of matter (core chemical entities)
   • Lead scaffolds, analogs, and closely related structural variants.
2. Formulations
   • Solid-state form (polymorph/amorphous),
   • salts,
   • particle size and dispersion,
   • release profiles (immediate vs modified release),
   • tablet/capsule excipient systems.
3. Methods of use
   • Patient selection criteria (biomarkers such as ACLY pathway activity proxies),
   • specific indications (tumor types or metabolic conditions),
   • combination regimens (with immune checkpoint inhibitors, chemo, targeted agents),
   • dose and schedule.

How this impacts market exclusivity

• Even if a core compound patent approaches expiration, method-of-use and formulation patents can keep a product “protected” for litigation and settlement purposes.
• The “last mile” exclusivity is usually determined by:
  • whether method claims are tied to approved labeling, and
  • whether formulation patents are Orange Book-listed (for NDA-based generics).

---

When do ATP-citrate lyase inhibitor patents expire and how long does exclusivity last?

Featured snippet answer: Exclusivity is driven by the latest priority date among the relevant compound families plus regulatory exclusivity tied to approval type.

Timing mechanics

• Patent term in the US is based on filing date with possible adjustments; it is not a simple “class calendar.”
• Orphan drug exclusivity (if applicable) can create a long exclusivity floor even with earlier patents expiring.
• NCE exclusivity and data exclusivity can extend marketing protection independent of patent term.

What to look for in a real estate view

For each ACL inhibitor NDA, the controlling schedule typically includes:

• Latest composition-of-matter expiration
• Latest method-of-use expiration (if Orange Book-listed)
• Latest formulation expiration
• Regulatory exclusivity end date
• Launch and potential Paragraph IV filing windows for ANDAs

Outcome

• Market entry timing is controlled by the last enforceable patent listed for the approved indication rather than the earliest compound patent in the family.

---

What is Orange Book status for ACL inhibitors and which patents are listed?

Featured snippet answer: Orange Book status is product-specific; ACL inhibitors are protected only to the extent their approved formulations and indications map to listed patents.

Orange Book listing patterns that affect generic risk

• If the NDA lists multiple patents across different expiration dates:
  • challengers face multiple invalidity and non-infringement arguments
  • settlement often targets a negotiated “carve-out” period or launch-at-risk timing
• If patents are not Orange Book listed for a given NDA:
  • generics may still face method-of-use or unlisted enforcement via litigation, depending on claim type and labeling linkage

Market dynamics implication

• Where Orange Book is dense, generic developers optimize:
  • design-around strategies
  • timing for Paragraph IV certification
  • licensing of at least the closest method/formulation claims

---

Do Paragraph IV ANDA challenges pose material risk for ACL inhibitors?

Featured snippet answer: Paragraph IV risk is high only where the approved ACL inhibitor product is already near patent expiration and Orange Book listings are concentrated in expiring patents.

Typical Paragraph IV playbook in this space

• Challenge the earliest expiring patent first to gain entry leverage.
• Certify non-infringement for:
  • specific polymorph/salt claims
  • specific dosage form claims
• Attack validity on:
  • obviousness over close analogs
  • enablement or written description for broad formula coverage

Settlement dynamics likely in a “thick” patent environment

• In ACL inhibitor programs, where formulations and methods are often followed by multiple patent “generations,” settlements commonly:
  • set delayed launch dates,
  • include royalties,
  • require cross-licenses on certain design-arounds.

---

Is biosimilar entry relevant for ACL inhibitors?

Featured snippet answer: No standard biosimilar pathway applies because ACL inhibitors are small molecules, not biologics.

Regulatory implication

• Exclusivity and generic entry are managed under:
  • ANDA pathways for small-molecule generics,
  • patent litigation under Hatch-Waxman.

---

Which formulation patents commonly block generic ACL inhibitor entry?

Featured snippet answer: Formulation patents and solid-state form claims can be the most effective generic entry barrier late in exclusivity.

Solid-state and formulation claims

Typical claim structures that matter in infringement analyses:

• polymorph-specific “Form X” and characteristic peaks
• particle size distributions for bioavailability
• dissolution profiles for modified release
• salt/hydrate inclusion with narrow stability windows

Why this drives market delay

• Generic sponsors often prefer to use bioequivalent formulations, but:
  • if the listed formulation patents cover specific physicochemical properties,
  • they either need a design-around or a license.

---

What method-of-use patents can restrict competitors even if composition claims weaken?

Featured snippet answer: Method-of-use patents can remain enforceable and can control labeling-linked generics and “off-label” attempts depending on claim scope.

Method-of-use claim themes in metabolic and oncology ACLY hypotheses

• Treating cancer by inhibiting ACLY to alter lipid metabolism
• Combination regimens (biomarker-driven scheduling)
• Patient stratification tied to ACLY pathway activity proxies

Labeling linkage

• The more a method claim tracks approved labeling, the greater the leverage against generic marketing.

---

How do ACL inhibitors compare with other metabolic oncology targets on the patent landscape?

Featured snippet answer: ACLY inhibitor patent estates tend to be composition-heavy early and become method/formulation-heavy later, similar to other metabolic targets but with less “class” coverage and more drug-family specificity.

Comparison framework

• Binding pocket and SAR breadth
  • broader SAR families can support longer “family coverage” by follow-on filings
• Platform patent strategies
  • medicinal chemistry + solid-state claims increase defense depth
• Regulatory dependence
  • oncology approvals often produce method and combination claims that align with labeling.

---

What patent litigation affects ACL inhibitors and what settlement structures are common?

Featured snippet answer: Litigation is typically driven by Orange Book-listed patents plus unlisted method claims; settlements often trade earlier entry for royalties and/or design-around concessions.

Expected litigation “hot spots” in this class

• core compound validity challenges
• non-infringement based on:
  • salt form
  • polymorph selection
  • route of synthesis and impurity profiles (if tied to manufacturing claims)
• method-of-use infringement tied to labeling instructions

Settlement structures

• delayed generic launch,
• “carve-out” from specific indications or dosages,
• licensing of the most directly infringed formulation/form variant,
• mutual covenants not to sue within defined claim sets.

---

What manufacturing process patents can create barriers to generic ACL inhibitor supply?

Featured snippet answer: Process and impurity patents can block or raise costs for generic manufacturing even if composition claims are partially designed around.

Process patent coverage themes

• specific steps in synthesis with critical temperature/time conditions
• intermediate purification steps
• impurity control thresholds and analytical targets

Practical effect

• Generic manufacturers may need:
  • alternative synthetic routes,
  • tighter impurity analytics,
  • extra validation for bioequivalence using the alternative route product.

---

Which geographic jurisdictions matter most for ACL inhibitor patent enforcement?

Featured snippet answer: US is decisive for generic entry timing; Europe and key Asian markets shape parallel enforcement and sales capture.

Jurisdictional enforcement logic

• US:
  • Orange Book listing drives Hatch-Waxman litigation timelines
• Europe:
  • EPO/EP patents and national validations determine infringement and injunction leverage
• UK:
  • post-Brexit continuation of EPC validation frameworks
• Key Asia (where commercial pull-through occurs):
  • enforcement depends on local patent registrations and court systems.

---

Revenue exposure: where do ACL inhibitors sit in the value chain?

Featured snippet answer: Revenue exposure is concentrated in the lead NDA and any combination-labeled indication expansions; pipeline bets are leveraged via partnerships.

Commercial risk drivers

• rapid line extensions in oncology can move the commercial center of gravity
• exclusivity extension depends on whether:
  • new formulations are patent-protected and label-relevant
  • new combinations trigger method-of-use coverage

---

How strong is the patent estate for ACL inhibitors and what are the weak points generics target?

Featured snippet answer: Strength usually comes from cumulative filing depth across compound, form, and method; weakness is concentrated in claim breadth that invites obviousness/anticipation attacks.

Common weak points in small-molecule estates

• overbroad genus claims that read on prior art analogs
• enablement gaps for very broad formula ranges
• “late” broad follow-on claims that exceed early disclosure support

Common generic design-around targets

• switching salt/polymorph selection
• changing formulation excipient systems tied to dissolution claims
• altering dosage form rather than active ingredient (when permitted)

---

What generic launch scenarios exist for ACL inhibitors?

Featured snippet answer: Three launch scenarios dominate: launch at risk, licensed entry, or delayed entry after settlement.

Scenario map

• Launch at risk
  • challenger believes patents are invalid or not infringed
• Licensed entry
  • challenger accepts a royalty to secure predictable launch timing
• Settlement-driven delay
  • delayed launch in exchange for avoiding litigation costs and injunction risk.

---

Key Takeaways

• ACL inhibitor (ACLY inhibitor) protection is rarely “one patent.” It is a layered estate spanning composition, solid-state/formulation, and method-of-use claims.
• Exclusivity duration is determined by the latest enforceable patent(s) tied to Orange Book listings and approved labeling, not the earliest compound filings.
• Paragraph IV risk is concentrated near expiration and increases when Orange Book lists multiple late-expiring patents.
• Formulation and solid-state patents often control the final competitive gap.
• Biosimilar pathways are not applicable because these are small molecules.

---

FAQs

1. How do solid-state form patents for ACL inhibitors affect ANDA bioequivalence strategies?
2. What certifications do ANDA filers use when ACL inhibitor Orange Book patents include formulation and method-of-use claims?
3. Can method-of-use ACL inhibitor patents block generic marketing even if composition-of-matter patents expire?
4. What litigation settlement terms are most common for small-molecule oncology exclusivity in this class?
5. Which factors most influence whether an ACL inhibitor estate is enforceable across the US and Europe?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
2. FDA. Hatch-Waxman Drug Products and Regulatory Exclusivity. US Food and Drug Administration.
3. United States Patent and Trademark Office (USPTO). Patent term and adjustments overview. USPTO.
4. US Code. 21 U.S.C. § 355 (Hatch-Waxman provisions). Legal Information Institute.